FDA Approves Eli Lilly's Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes Patients
Science & ClimateWell-covered
|
The Facts
- The FDA approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.
- The new indication covers cardiovascular death, non-fatal heart attack and non-fatal stroke.
- Eli Lilly announced the approval on Friday, August 28, 2026.
- Mounjaro was already approved as an adjunct to diet and exercise to improve blood sugar in people aged 10 and older with type 2 diabetes.
- The approval was based on SURPASS-CVOT, a cardiovascular outcomes trial enrolling 13,299 participants.
- In the trial, Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Trulicity.
- Lilly reported second-quarter Mounjaro sales of $9.94 billion, up 91% from a year earlier.
- Lilly markets the same active ingredient, tirzepatide, as Zepbound for obesity in the United States.
- Lilly says as many as one in three U.S. adults with type 2 diabetes have undetected cardiovascular disease.
- Novo Nordisk won FDA approval in 2024 for Wegovy to reduce cardiovascular risk in overweight or obese adults without diabetes.
Context
What was different about the trial behind this approval?
SURPASS-CVOT was described as the first cardiovascular outcomes trial to compare two incretin medicines directly against each other rather than against a placebo, pitting Mounjaro against Lilly's older drug Trulicity (dulaglutide) Quartz,GEO TV. It enrolled 13,299 participants across 30 countries over more than four and a half years Quartz. Mounjaro cleared the trial's noninferiority hurdle and showed an 8% lower rate of the combined endpoint Yahoo! Finance,Metro.
Why does the label expansion matter for patients and for Lilly?
Lilly said heart disease is the leading cause of death for people with type 2 diabetes, and executive Kenneth Custer said the drug now gives them 'a proven way to lower that risk' Independent,GEO TV,Metro. Commercially, the expanded indication moves Mounjaro beyond blood-sugar control and gives physicians another reason to prescribe it in the cardiometabolic market, where Lilly competes with Novo Nordisk Yahoo! Finance,Yahoo! Finance,Bloomberg Business.
How does this fit into the broader push to expand GLP-1 drug uses?
Manufacturers including Lilly and Novo Nordisk are testing GLP-1 medicines across additional conditions, with approvals or studies covering cardiovascular disease, sleep apnea, liver disease, chronic kidney disease and alcohol use disorder Terra,Independent,Money Times. A mid-stage University of North Carolina study of 48 adults examined semaglutide in alcohol use disorder, while results in Alzheimer's-related cognitive decline have been unfavorable Independent,Terra.
Where Left and Right agree, and where they split
- Where Left and Right agree
- The 8% reduction in cardiovascular death, heart attack and stroke, measured in 13,299 patients against an active comparator, is a real clinical gain neither framing discounts.
- Where Left and Right split
- Whether the story is about who can afford a drug booking $9.94 billion a quarter, or about evidence clearing a high bar and leaving the prescribing call to doctors and patients.
- Why they won’t converge
- The divide is about values, not evidence: both sides accept the 8% result, but one treats a proven benefit as creating a public claim on payers, the other treats it as settling only what a doctor and patient may choose.
How left and right read it
An 8% lower rate of cardiovascular death, heart attack and stroke in high-risk adults with type 2 diabetes is a public-health gain, so it should not be rationed by income — yet the same molecule already booked $9.94 billion in a single quarter, up 91%. Manufacturers keep broadening these drugs' approved uses. Coverage must widen with them: pay for it, alongside diet and exercise.
“The decision marks the latest step by manufacturers of GLP-1 drugs to broaden the clinical scope of their treatments.” — The Independent
A company that wants a broader label should have to earn it against a real benchmark, and Lilly did: SURPASS-CVOT enrolled 13,299 patients and measured tirzepatide against Trulicity, its own older drug, producing an 8% lower rate of cardiovascular death, heart attack or stroke. That is a high bar cleared. Because the evidence carried the day, the decision on who takes it belongs to doctors and patients — not to anyone else.
The receipts — all 47 sources
Wire services (2)
Independent coverage (45)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.